Potential biomarkers in endometrial cancer: a narrative review

References

• Akhtar, M., et al., 2019. Classification of endometrial carcinoma: new perspectives beyond morphology. Advances in anatomic pathology, 26, 421–427.
   PubMed Web of Science ®Google Scholar
• Al-Maghrabi, J.A., et al., 2016. Clusterin immunoexpression is associated with early stage endometrial carcinomas. Acta histochemica, 118 (4), 430–434.
   PubMed Web of Science ®Google Scholar
• Alexa, M., Hasenburg, A., and Battista, M.J., 2021a. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers, 13, 1478.
   PubMed Web of Science ®Google Scholar
• Ali, A.T., 2014. Reproductive factors and the risk of endometrial cancer. International journal of gynecologic cancer, 24, 384–393.
   PubMed Web of Science ®Google Scholar
• Allard, J.E., et al., 2007. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecologic oncology, 107 (1), 52–57.
   PubMed Web of Science ®Google Scholar
• Alonso-Alconada, L., et al., 2015. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. International journal of cancer, 136 (8), 1863–1873.
   PubMed Web of Science ®Google Scholar
• Álvarez-Garcia, V., et al., 2019. Mechanisms of PTEN loss in cancer: it’s all about diversityed. In: Seminars in cancer biology. Elsevier, 66–79.
   Google Scholar
• Arciuolo, D., et al., 2022. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. International journal of molecular sciences, 23, 11684.
   PubMed Web of Science ®Google Scholar
• Ayhan, A., et al., 2001. Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecologic oncology, 80 (3), 355–358.
   PubMed Web of Science ®Google Scholar
• Backes, F.J., et al., 2019. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. Cancer, 125 (3), 398–405.
   PubMed Web of Science ®Google Scholar
• Backes, F.J., et al., 2016. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecologic oncology, 141 (2), 312–317.
   PubMed Web of Science ®Google Scholar
• Baron, J.A., et al., 2021. Cigarette smoking and estrogen-related cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American association for cancer research, cosponsored by the American society of preventive oncology, 30 (8), 1462–1471.
   PubMed Web of Science ®Google Scholar
• Barry, J.A., Azizia, M.M., and Hardiman, P.J., 2014. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction update, 20 (5), 748–758.
   PubMed Web of Science ®Google Scholar
• Behrouzi, R., Barr, C.E., and Crosbie, E.J., 2021. HE4 as a biomarker for endometrial cancer. Cancers, 13, 4764.
   PubMedGoogle Scholar
• Benati, M., et al., 2018. The clinical significance of DJ-1 and HE 4 in patients with endometrial cancer. Journal of clinical laboratory analysis, 32, e22223.
   PubMed Web of Science ®Google Scholar
• Berger, A.A., Dao, F., and Levine, D.A., 2021. Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives. Gynecologic oncology, 160 (3), 844–850.
   PubMed Web of Science ®Google Scholar
• Boroń, D., et al., 2022. Recent multiomics approaches in endometrial cancer. International journal of molecular sciences, 23, 1237.
   PubMed Web of Science ®Google Scholar
• Brett, M.A., et al., 2021. Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma. International journal of gynecological pathology : official journal of the international society of gynecological pathologists, 40 (2), 116–123.
   PubMed Web of Science ®Google Scholar
• Buza, N., 2021. HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Archives of pathology & laboratory medicine, 145, 687–691.
   PubMed Web of Science ®Google Scholar
• Chang, Z., et al., 2019. Molecular characterization of endometrial cancer and therapeutic implications. Current opinion in obstetrics and gynecology, 31, 24–30.
   PubMed Web of Science ®Google Scholar
• Chen, Q., et al., 2019. Circulating cell-free DNA or circulating tumor DNA in the management of ovarian and endometrial cancer. OncoTargets and therapy, 12, 11517.
   PubMed Web of Science ®Google Scholar
• Christensen, M.V., et al., 2018. Annexin A2 and cancer: A systematic review. International journal of oncology, 52, 5–18.
   PubMed Web of Science ®Google Scholar
• Church, D.N., et al., 2013. DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer. Human molecular genetics, 22, 2820–2828.
   PubMed Web of Science ®Google Scholar
• Clarke, M.A., et al., 2018. Association of endometrial cancer risk with postmenopausal bleeding in women: A systematic review and meta-analysis. JAMA internal medicine, 178, 1210–1222.
   PubMed Web of Science ®Google Scholar
• Degez, M., et al., 2021. Endometrial cancer: A systematic review of HE4, REM and REM-B. Clinica chimica acta, 515, 27–36.
   PubMed Web of Science ®Google Scholar
• Deng, L., et al., 2015. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. Journal of experimental & clinical cancer research, 34, 1–11.
   PubMed Web of Science ®Google Scholar
• Deng, L., Liang, H., and Han, Y.J.F.I.O., 2020. Cyclooxygenase-2 and β-catenin as potential diagnostic and prognostic markers in endometrial cancer. Frontiers in oncology, 10, 56.
   PubMed Web of Science ®Google Scholar
• Di Cello, A., et al., 2017. DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer. Tumour biology : the journal of the international society for oncodevelopmental biology and medicine, 39 (6), 1010428317705746.
   Google Scholar
• Dimou, N., et al., 2022. Cigarette smoking and endometrial cancer risk: Observational and mendelian randomization analyses. Cancer epidemiology, biomarkers & prevention : a publication of the American association for cancer research, cosponsored by the American society of preventive oncology, 31 (9), 1839–1848.
   PubMed Web of Science ®Google Scholar
• Donkers, H., et al., 2021. Usefulness of microRNA detection in the diagnostics of endometrial cancer. Acta obstetricia et gynecologica scandinavica, 100 (6), 1148–1154. &,
   PubMed Web of Science ®Google Scholar
• Elbasateeny, S.S., et al., 2016. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathology, research and practice, 212 (1), 10–16.
   PubMed Web of Science ®Google Scholar
• Espiau Romera, A., et al., 2020. HE 4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer. International journal of gynecology & obstetrics, 149, 265–268.
   PubMed Web of Science ®Google Scholar
• Esposito, G., et al., 2021. Diabetes risk reduction diet and endometrial cancer risk. Nutrients, 13 (8), 2630.
   Web of Science ®Google Scholar
• Fadare, O., et al., 2013. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Modern pathology, 26, 1101–1110.
   PubMed Web of Science ®Google Scholar
• Fan, X., et al., 2021. MicroRNA expression profile in serum reveals novel diagnostic biomarkers for endometrial cancer. Bioscience reports, 41.
   Web of Science ®Google Scholar
• Felder, M., et al., 2014. MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress. Molecular cancer, 13, 1–15.
   PubMed Web of Science ®Google Scholar
• Feng, W., et al., 2021. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer. Journal of translational medicine, 19, 1–11.
   PubMed Web of Science ®Google Scholar
• Fiala, L., Bob, P., and Raboch, J., 2018. Oncological markers CA-125, CA 19-9 and endometriosis. Medicine, 97, e13759.
   PubMed Web of Science ®Google Scholar
• Fuzio, P., et al., 2013. Regulation of the expression of CLU isoforms in endometrial proliferative diseases. International journal of oncology, 42 (6), 1929–1944.
   PubMed Web of Science ®Google Scholar
• Garikapati, K.K., et al., 2019. Type-II endometrial cancer: Role of adipokines. Archives of gynecology and obstetrics, 300 (2), 239–249.
   PubMed Web of Science ®Google Scholar
• Genchi, V.A., et al., 2021. Impaired leptin signalling in obesity: Is leptin a new thermolipokine? International journal of molecular sciences, 22, 6445.
   PubMed Web of Science ®Google Scholar
• Gong, T.-T., Wang, Y.-L., and Ma, X.-X., 2015. Age at menarche and endometrial cancer risk: A dose-response meta-analysis of prospective studies. Scientific reports, 5, 14051.
   PubMed Web of Science ®Google Scholar
• Guan, Y., et al., 2018. Prioritizing predictive biomarkers for gene essentiality in cancer cells with mRNA expression data and DNA copy number profile. Bioinformatics, 34, 3975–3982.
   PubMed Web of Science ®Google Scholar
• Hanson, B., et al., 2017. Female infertility, infertility-associated diagnoses, and comorbidities: a review. Journal of assisted reproduction and genetics, 34, 167–177.
   PubMed Web of Science ®Google Scholar
• Harris, R.A., and Fenton, A.W., 2019. A critical review of the role of M2PYK in the Warburg effect. Biochimica et biophysica acta. Reviews on cancer, 1871 (2), 225–239.
   PubMed Web of Science ®Google Scholar
• Hlavna, M., et al., 2011. Relationship of resistin levels with endometrial cancer risk. Neoplasma, 58 (2), 124–128.
   PubMed Web of Science ®Google Scholar
• Hosseini Nasab, S., et al., 2018. Using pyruvate kinase as a predictor for patient with endometrial cancer having complex hyperplasia with atypia to prevent hysterectomy and preserve fertility: Retrospective immunohistochemical study. Reproductive sciences (Thousand Oaks, Calif.), 25 (8), 1286–1291.
   PubMed Web of Science ®Google Scholar
• Hutt, S., et al., 2019. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta oncologica, 58, 342–352.
   PubMed Web of Science ®Google Scholar
• Imboden, S., et al., 2019. Phenotype of POLE-mutated endometrial cancer. PLOS one, 14 (3), e0214318.
   PubMed Web of Science ®Google Scholar
• Israelsen, W. J., and Vander Heiden, M. G., 2015. Pyruvate kinase: Function, regulation and role in cancered. In: Seminars in cell & developmental biology. Elsevier, 43–51.
   Google Scholar
• Jayanthi, V.S.A., Das, A.B., and Saxena, U., 2017. Recent advances in biosensor development for the detection of cancer biomarkers. Biosensors and bioelectronics, 91, 15–23.
   PubMed Web of Science ®Google Scholar
• Jia, W., et al., 2013. Identification of four serum microRNAs from a genome‑wide serum microRNA expression profile as potential non‑invasive biomarkers for endometrioid endometrial cancer. Oncology letters, 6, 261–267.
   PubMed Web of Science ®Google Scholar
• Jiang, S.-W., et al., 2008. Application of DNA methylation biomarkers for endometrial cancer management. Expert review of molecular diagnostics, 8 (5), 607–616.
   PubMed Web of Science ®Google Scholar
• Kato, A., et al., 2016. Isolated loss of PMS2 immunohistochemical expression is frequently caused by heterogenous MLH1 promoter hypermethylation in Lynch syndrome screening for endometrial cancer patients. The American journal of surgical pathology, 40, 770.
   PubMed Web of Science ®Google Scholar
• Kaur, R.P., et al., 2018. Role of p53 gene in breast cancer: Focus on mutation spectrum and therapeutic strategies. Current pharmaceutical design, 24 (30), 3566–3575.
   PubMed Web of Science ®Google Scholar
• Khan, W.A., Alsamghan, A.S., and Khan, M.W.A., 2020. Endometrial cancer patients have high affinity antibodies for estrogen metabolite–receptor aggregate: A potential biomarker for EC. The journal of obstetrics and gynaecology research, 46 (10), 2115–2125.
   PubMed Web of Science ®Google Scholar
• Kim, J.J., Sefton, E.C., and Bulun, S.E., 2009. Progesterone receptor action in leiomyoma and endometrial cancer. Progress in molecular biology and translational science, 87, 53–85.
   PubMed Web of Science ®Google Scholar
• Kobayashi Kato, M., et al., 2022. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma. Cancer science, 113 (5), 1712–1721.
   PubMed Web of Science ®Google Scholar
• Köbel, M., et al., 2019. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. International journal of gynecological pathology, 38, S123.
   PubMed Web of Science ®Google Scholar
• Kolb, R., Sutterwala, F.S., and Zhang, W., 2016. Obesity and cancer: Inflammation bridges the two. Current opinion in pharmacology, 29, 77–89.
   PubMed Web of Science ®Google Scholar
• Krishnamurti, U., and Silverman, J.F., 2014. HER2 in breast cancer: A review and update. Advances in anatomic pathology, 21 (2), 100–107.
   PubMed Web of Science ®Google Scholar
• Kumar, N.U., et al., 2018. CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding. African health sciences, 18, 972–978.
   PubMed Web of Science ®Google Scholar
• La Vecchia, C., 2006. Oral contraceptives and ovarian cancer: An update, 1998–2004. European journal of cancer prevention : the official journal of the european cancer prevention organisation (ECP), 15 (2), 117–124.
   PubMed Web of Science ®Google Scholar
• Lai, Y.-J., et al., 2019. Pyruvate kinase M2 expression: A Potential Metabolic Biomarker To Differentiate Endometrial Precancer And Cancer That Is Associated With Poor Outcomes In Endometrial Carcinoma. International journal of environmental research and public health, 16, 4589.
   PubMed Web of Science ®Google Scholar
• Leblanc, M., et al., 2001. Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows archiv : an international journal of pathology, 438 (1), 78–85.
   PubMed Web of Science ®Google Scholar
• Lech, G., et al., 2016. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World journal of gastroenterology, 22 (5), 1745–1755.
   PubMed Web of Science ®Google Scholar
• Lee, Y.S., and Dutta, A., 2009. MicroRNAs in cancer. Annual review of pathology: Mechanisms of disease, 4, 199–227.
   PubMed Web of Science ®Google Scholar
• Li, M., and Zhou, C., 2021. Progesterone receptor gene serves as a prognostic biomarker associated with immune infiltration in gastric cancer: a bioinformatics analysis. Translational cancer research, 10, 2663.
   PubMed Web of Science ®Google Scholar
• Li, S., et al., 2019a. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis, 22, 15–36.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2019b. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. BMC medical genetics, 20, 1–13.
   PubMed Web of Science ®Google Scholar
• Li, Z., et al., 2021. Valproic acid suppresses breast cancer cell growth through triggering pyruvate kinase M2 isoform mediated Warburg effect. Cell transplantation, 30, 09636897211027524.
   PubMed Web of Science ®Google Scholar
• Liang, J., and Shang, Y., 2013. Estrogen and cancer. Annual review of physiology, 75, 225–240.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Lian, T., and Yao, Y., 2020. A systematic review and meta-analysis of higher expression of folate receptor alpha (FOLR1) predicts poor cancer prognosis. Biomarkers, 25, 367–374.
   PubMed Web of Science ®Google Scholar
• Loukovaara, M., Pasanen, A., and Bützow, R. J.C.M., 2021. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer. Cancer medicine, 10 (3), 1034–1042.
   PubMed Web of Science ®Google Scholar
• Luhn, P., et al., 2013. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer epidemiology, biomarkers & prevention, 22, 1304–1312.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia, E., et al., 2017. Targeted proteomics identifies proteomic signatures in liquid biopsies of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal surgical treatment. Clinical cancer research, 23, 6458–6467.
   PubMed Web of Science ®Google Scholar
• Maxwell, G.L., et al., 2006. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecologic oncology, 103 (2), 535–540.
   PubMed Web of Science ®Google Scholar
• Mcdonald, M.E., and Bender, D.P., 2019. Endometrial cancer: Obesity, genetics, and targeted agents. Obstetrics and gynecology clinics of North america, 46 (1), 89–105.
   PubMed Web of Science ®Google Scholar
• Mitric, C., and Bernardini, M.Q., J.C.O., 2022. Endometrial cancer: Transitioning from histology to genomics. Current oncology (Toronto, Ont.), 29 (2), 741–757.
   PubMed Web of Science ®Google Scholar
• Mittica, G., et al., 2017. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 8 (52), 90532–90544.
   PubMedGoogle Scholar
• Moore, K., and Brewer, M.A., 2017. Endometrial cancer: is this a new disease? American society of clinical oncology educational book, 37, 435–442.
   PubMedGoogle Scholar
• Morelli, M., et al., 2014. DJ-1 in endometrial cancer: A possible biomarker to improve differential diagnosis between subtypes. International journal of gynecologic cancer, 24, 649–658.
   PubMed Web of Science ®Google Scholar
• Morielli, A.R., et al., 2022. Associations of insulin resistance and inflammatory biomarkers with endometrial cancer survival: The Alberta endometrial cancer cohort study. Cancer medicine, 11 (7), 1701–1711.
   PubMed Web of Science ®Google Scholar
• Moss, E.L., et al., 2020. Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression. Cancers, 12, 2231.
   PubMed Web of Science ®Google Scholar
• Muinelo-Romay, L., Casas-Arozamena, C., and Abal, M.J.I.J.O.M.S., 2018. Liquid biopsy in endometrial cancer: new opportunities for personalized oncology. International journal of molecular sciences, 19, 2311.
   PubMed Web of Science ®Google Scholar
• Murali, R., Soslow, R.A., and Weigelt, B., 2014. Classification of endometrial carcinoma: more than two types. The lancet oncology, 15, e268–e278.
   PubMed Web of Science ®Google Scholar
• Nilsson, S., and Gustafsson, J.-A., 2002. Estrogen receptor action. Critical reviews™ in eukaryotic gene expression, 12 (4), 12.
   Web of Science ®Google Scholar
• Nojadeh, J., Behrouz Sharif, S., and Sakhinia, E., 2018. Microsatellite instability in colorectal cancer. EXCLI J 17: 159–168. EXCLI journal experimental and clinical sciences, 17, 159–168.
   Google Scholar
• Olea-Flores, M., et al., 2020. New actors driving the epithelial–mesenchymal transition in cancer: The role of leptin. Biomolecules, 10, 1676.
   PubMed Web of Science ®Google Scholar
• Onstad, M.A., Schmandt, R.E., and Lu, K.H., 2016. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. Journal of clinical oncology : official journal of the American society of clinical oncology, 34 (35), 4225–4230.
   PubMed Web of Science ®Google Scholar
• Pabalan, N., et al., 2017. Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis. Gynecologic oncology, 146 (3), 603–608.
   PubMed Web of Science ®Google Scholar
• Parida, S., Siddharth, S., and Sharma, D., 2019. Adiponectin, obesity, and cancer: Clash of the bigwigs in health and disease. International journal of molecular sciences, 20 (10), 2519.
   PubMed Web of Science ®Google Scholar
• Paterson, E., et al., 2022. Recommendations for extracellular vesicle miRNA biomarker research in the endometrial cancer context. Translational oncology, 23, 101478.
   PubMed Web of Science ®Google Scholar
• Piltonen, T.T., 2016. Polycystic ovary syndrome: Endometrial markers. Best practice & research. Clinical obstetrics & gynaecology, 37, 66–79.
   PubMed Web of Science ®Google Scholar
• Post, C., et al., 2021. Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer. Journal of the national cancer institute, 113 (9), 1212–1220.
   PubMedGoogle Scholar
• Proietti, C.J., Cenciarini, M.E., and Elizalde, P.V., 2018. Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions. Steroids, 133, 75–81.
   PubMed Web of Science ®Google Scholar
• Raglan, O., et al., 2019. Risk factors for endometrial cancer: An umbrella review of the literature. International journal of cancer, 145 (7), 1719–1730.
   PubMed Web of Science ®Google Scholar
• Relton, A., et al., 2021. Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up. European journal of cancer care, 30 (4), e13429.
   PubMed Web of Science ®Google Scholar
• Roškar, L., et al., Š., 2021. Tie-2, G-CSF, and Leptin as promising diagnostic biomarkers for endometrial cancer: A pilot study. Journal of clinical medicine, 10, 765.
   PubMed Web of Science ®Google Scholar
• Senol, S., et al., 2015. Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia. International journal of clinical and experimental pathology, 8 (5), 5633–5641.
   PubMed Web of Science ®Google Scholar
• Shabayek, M.I., et al., 2014. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer. Pathology oncology research : POR, 20 (4), 859–866.
   PubMed Web of Science ®Google Scholar
• Simmons, A.R., Baggerly, K., and Bast, R.C., Jr, 2013. The emerging role of HE4 in the evaluation of advanced epithelial ovarian and endometrial carcinomas. Oncology (williston park, NY, 27, 548. ),
   PubMed Web of Science ®Google Scholar
• Slabuszewska-Józwiak, A., et al., 2022. Role of leptin and adiponectin in endometrial cancer. International journal of molecular sciences, 23 (10), 5307.
   PubMed Web of Science ®Google Scholar
• Socol, C.T., et al., 2022. Leptin signaling in obesity and colorectal cancer. International journal of molecular sciences, 23, 4713.
   PubMed Web of Science ®Google Scholar
• Stelloo, E., et al., 2017. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Annals of oncology : official journal of the European society for medical oncology, 28 (1), 96–102.
   PubMed Web of Science ®Google Scholar
• Travaglino, A., et al., 2020. TCGA classification of endometrial cancer: The place of carcinosarcoma. Pathology oncology research: POR, 26 (4), 2067–2073.
   PubMed Web of Science ®Google Scholar
• Travaglino, A., et al., 2022. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: A systematic review and meta-analysis. Archives of gynecology and obstetrics, 306 (2), 1–9.
   Google Scholar
• Tripathi, D., et al., 2020. Resistin in metabolism, inflammation, and disease. The FEBS journal, 287 (15), 3141–3149.
   PubMed Web of Science ®Google Scholar
• Trojano, G., et al., 2019. Conservative treatment in early stage endometrial cancer: A review. Acta biomedica atenei parmensis, 90, 405–410.
   PubMedGoogle Scholar
• Tumminia, A., et al., 2019. Adipose tissue, obesity and adiponectin: Role in endocrine cancer risk. International journal of molecular sciences, 20, 2863.
   PubMed Web of Science ®Google Scholar
• Van Den Helder, R., et al., 2020. Non-invasive detection of endometrial cancer by DNA methylation analysis in urine. Clinical epigenetics, 12, 1–7.
   Web of Science ®Google Scholar
• Vermij, L., et al., 2021. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. Histopathology, 79, 533–543.
   PubMed Web of Science ®Google Scholar
• Weiderpass, E., et al., 1999. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer causes & control : CCC, 10 (4), 277–284.
   PubMed Web of Science ®Google Scholar
• Wu, Y.-S., et al., 2019. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer. Gene, 697, 86–93.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2015. Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer. Cancer biomarkers., 15, 205–211.
   PubMed Web of Science ®Google Scholar
• Zhan, B., et al., 2015. Breastfeeding and the incidence of endometrial cancer: A meta-analysis. Oncotarget, 6, 38398.
   PubMedGoogle Scholar
• Zhang, H., et al., 2016. Role of liquid-based cytology and cell block in the diagnosis of endometrial lesions. Chinese medical journal, 129, 1459–1463.
   PubMed Web of Science ®Google Scholar
• Zhang, J., et al., 2019. Polycystic ovary syndrome and mitochondrial dysfunction. Reproductive biology and endocrinology, 17, 67.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2020. Role of DJ-1 in immune and inflammatory diseases. Frontiers in immunology, 11, 994.
   PubMedGoogle Scholar
• Zhang, Y., et al., 2015. Prognostic role of hormone receptors in endometrial cancer: A systematic review and meta-analysis. World journal of surgical oncology, 13, 1–12.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2018. Δ 9‑tetrahydrocannabinol inhibits epithelial‑mesenchymal transition and metastasis by targeting matrix metalloproteinase‑9 in endometrial cancer. Oncology letters, 15, 8527–8535.
   PubMed Web of Science ®Google Scholar
• Zheng, Q., Wu, H., and Cao, J., 2015. Circulating adiponectin and risk of endometrial cancer. PLOS one, 10 (6), e0129824.
   PubMed Web of Science ®Google Scholar
• Zhou, L., et al., 2021. Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Molecular cancer, 20, 1–6.
   PubMed Web of Science ®Google Scholar